Dyax Announces FDA Approval of KALBITOR® (ecallantide) for the Treatment of Acute Attacks of Hereditary Angioedema in Patients 16 Years of Age and Older

U.S. Food and Drug Administration (FDA) has granted approval of KALBITOR® (ecallantide) for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. KALBITOR is the first subcutaneous treatment approved for HAE. (Photo: Business Wire)

HAE Patient Before and During an Acute Hereditary Angioedema (HAE) Attack. HAE attacks can occur in the abdomen, face, hands, feet and airway. This photo shows an example of a facial attack. (Photo: Business Wire)

Full Prescribing Information for KALBITOR® (ecallantide)